| 1.34 -0.09 (-6.29%) | 01-23 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.73 |
1-year : | 1.93 |
| Resists | First : | 1.48 |
Second : | 1.65 |
| Pivot price | 1.39  |
|||
| Supports | First : | 1.19 |
Second : | 0.99 |
| MAs | MA(5) : | 1.39 |
MA(20) : | 1.36 |
| MA(100) : | 1.51 |
MA(250) : | 1.96 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 41 |
D(3) : | 43.5 |
| RSI | RSI(14): 48.2 |
|||
| 52-week | High : | 4.48 | Low : | 0.87 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ BMEA ] has closed above bottom band by 34.3%. Bollinger Bands are 27.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.43 - 1.44 | 1.44 - 1.45 |
| Low: | 1.31 - 1.32 | 1.32 - 1.33 |
| Close: | 1.33 - 1.34 | 1.34 - 1.35 |
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.
Sat, 24 Jan 2026
Biomea Fusion, Inc.'s (NASDAQ:BMEA) largest shareholders are retail investors with 55% ownership, institutions own 38% - Yahoo Finance
Wed, 21 Jan 2026
Biomea Fusion, Inc. (NASDAQ:BMEA) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Mon, 19 Jan 2026
Rodman & Renshaw Initiates Biomea Fusion (BMEA) at Buy with $8 Price Target - Finviz
Mon, 12 Jan 2026
Biomea Fusion outlines 2026 diabetes and obesity drug development plans - Investing.com
Mon, 12 Jan 2026
Biomea Fusion Enters 2026 Focused on Executing Key Icovamenib and BMF-650 Milestones - GlobeNewswire
Sat, 27 Dec 2025
Biomea Fusion, Inc. (NASDAQ:BMEA) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 71 (M) |
| Shares Float | 66 (M) |
| Held by Insiders | 8 (%) |
| Held by Institutions | 37.1 (%) |
| Shares Short | 9,470 (K) |
| Shares Short P.Month | 8,440 (K) |
| EPS | -2.25 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.25 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -75.3 % |
| Return on Equity (ttm) | -209 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.39 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -86 (M) |
| Levered Free Cash Flow | -56 (M) |
| PE Ratio | -0.6 |
| PEG Ratio | 0 |
| Price to Book value | 5.15 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.1 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|